Luis Corrales

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg et al. · The Lancet · 2021 · 313 citations · Full text

Urology, Oncology, Genitourinary Cancer +6

Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

Óscar Arrieta, Andrés F. Cardona, Claudio Martín et al. · Journal of Thoracic Oncology · 2015 · 190 citations · Full text

Kras Mutations, Oncology, Cancer Epidemiology +10

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations

Jian Carrot‐Zhang, Giovanny Soca‐Chafre, Nick Patterson et al. · Cancer Discovery · 2020 · 142 citations · Full text